News

Genzyme boosts Sanofi earnings
Enlarge image

BusinessFrance

Genzyme boosts Sanofi earnings

30.04.2012 - The acquisition of Genzyme shows its benefits: Sanofi reported strong
sales and earnings growth in the first quarter of 2012.

Paris –  The French drug maker reported a net profit of €1.8bn, up from €1.2bn in the first quarter of 2011. The better earnings, however, were not enough to change the company's gloomy outlook for the coming year.  The executives warned that earnings in the rest of the year would be hit by the loss of US market exclusivity of its blood thinner Plavix (clopidogrel) in May, and blood pressure drug Avapro (irbesartan) at the end of March. Net sales rose more than 9% to €8.5bn, with revenue at the flagship pharmaceutical division, increasing 8.8% at constant exchange rates, to €7.32bn.

Genzyme contributed €841m. Sanofi benefited from growth in emerging markets (+9.9% to €2.6bn), with Brazil, Russia, Indian and China together contributing €917m. Sanofi's diabetes franchise also increased by 14.4% to €1.3bn. The contribution of Lantus (insulin glargine) is €1.1bn (+17.2%), which means it is the company's top-selling drug. Sanofi's oncology business grew by 12.8% to €741m, with Eloxatin (oxaliplatin) generating €321m in the US.

Sanofi's CEO Chris Viehbacher emphasised that the patent loss of former key products like Plavix and Avapro had been something the French multinational had long foreseen. According to Viehbacher, the company is now entering the final phase of its patent cliff. He said that Sanofi had built six "growth platforms" to replace sales lost to generic competition and generate sustainable growth. He noted that these new products would not be dependent on patents to the same extent. Growth platform businesses include Genzyme developments – including rare disease products like Cerezyme and Fabrazyme, plus the late-stage multiple sclerosis products Aubagio (teriflunomide) and Lemtrada (alemtuzumab). Other growth platforms are diabetes, vaccines, consumer health care, animal health, new products and emerging markets.

http://www.european-biotechnology-news.com/news/news/2012-02/genzyme-boosts-sanofi-earnings.html

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)1.50 EUR12.78%
  • BIOCARTIS GROUP NV (B)7.57 EUR7.53%
  • SWEDISH ORPHAN BIOVITRUM (S)13.11 USD6.59%

FLOP

  • NICOX (F)11.57 EUR-8.61%
  • KAROLINSKA (S)7.55 SEK-4.43%
  • AB SCIENCE (F)14.20 EUR-4.05%

TOP

  • PROTHENA PLC (IE)53.17 USD49.9%
  • FLAMEL TECHNOLOGIES (F)12.49 USD32.2%
  • TIGENIX (B)1.05 EUR26.5%

FLOP

  • MOLOGEN (D)1.50 EUR-40.0%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SANTHERA (CH)56.75 CHF-18.9%

TOP

  • KARO BIO (S)28.70 SEK1705.0%
  • NICOX (F)11.57 EUR493.3%
  • SAREUM HOLDINGS (UK)0.64 GBP166.7%

FLOP

  • BB BIOTECH (D)45.22 EUR-84.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.64 SEK-79.3%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 23.07.2016